Targets › TOPO1
19 programs from 17 companies in 28 trials: 13 Phase 2, 11 Phase 3, 4 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: the race on TOPO1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Assistance Publique - Hôpitaux de Paris | Modified FOLFIRINOX Combination chemotherapy: topoisomerase I inhibitor (irinotecan), topoisomerase II inhibit | TOPO1, TOPO2A, MTHFR, TYMS | Phase 3 | Rectal Cancer | Dec 2026 |
| Sun Yat-sen University | mFOLFOXIRI Multi-drug chemotherapy regimen: oxaliplatin (platinum-based DNA crosslinker), irinotecan | TOPO1, TOPO2A, ERCC1 | Phase 3 | Colon Cancer Stage II | Dec 2026 |
| Genmab | Rina-S Topoisomerase 1 inhibitor conjugate (SN-38 payload on anti-TROP-2 antibody) | TOPO1 | Phase 3 | Platinum-resistant Ovarian Cancer; Ovarian Cancer; Endometrial Cancer; Platinum-Sensitive Ovarian Cancer … | Sep 2027 |
| Dominik Paul Modest | mFOLFOXIRI Combination chemotherapy: topoisomerase I inhibitor (irinotecan), topoisomerase II inhibit | TOPO1, TOPO2A | Phase 3 | Colorectal Cancer | Nov 2027 |
| Seoul National University Hospital | mFOLFIRINOX (preoperative) Multi-agent chemotherapy combining irinotecan (topoisomerase I inhibitor), fluorouracil (t | TOPO1, DHFR, TYMS | Phase 3 | Resectable Pancreatic Cancer | Dec 2027 |
| Fudan University | mFOLFIRINOX adjuvant chemotherapy Multi-agent chemotherapy: oxaliplatin (platinum agent), irinotecan (topoisomerase I inhibi | DHFR, TYMS, TOPO1, SLC22A16 | Phase 3 | High-risk Stage II Colorectal Cancer | Jun 2028 |
| National Cancer Center Hospital East | CAPOXIRI Combination chemotherapy: capecitabine (5-FU prodrug), oxaliplatin (platinum agent), and i | DPYD, TOPO1, XRCC1 | Phase 3 | Locally Advanced Rectal Cancer | Dec 2029 |
| Rutgers, The State University of New Jersey | sFOLFOXIRI (alternating FOLFOX and FOLFIRI) Fluorouracil-based chemotherapy combining FOLFOX (5-fluorouracil, leucovorin, oxaliplatin) | DHFR, TYMS, TOPO1 | Phase 2 | Gastro-Intestinal Cancer | Feb 2027 |
| Centre Hospitalier Universitaire Dijon | FOLFOXIRI Protocol (modified FOLFIRINOX) Combination chemotherapy: irinotecan (TOPO1 inhibitor) + oxaliplatin (TOPO2 inhibitor) + f | TOPO1, TOPO2, TYMS | Phase 2 | Locally Advanced or Metastatic Small Bowel Adenocarcinoma; Neuroendocrine Carcinoma | Feb 2027 |
| Seoul National University Bundang Hospital | mFOLFOX/mFOLFIRI Combination of fluorouracil with oxaliplatin and irinotecan | TOPO1, TOPO2A | Phase 2 | Biliary Cancer Metastatic | Apr 2027 |
| Peking Union Medical College Hospital | NALIRIFOX Combination chemotherapy (liposomal irinotecan, oxaliplatin, leucovorin); irinotecan is a | TOPO1 | Phase 2 | Locally Advanced Pancreatic Cancer | May 2027 |
| Fudan University | mFOLFIRINOX plus IMRT Multi-drug chemotherapy regimen (5-fluorouracil, folinic acid, irinotecan, oxaliplatin) co | TOPO1, DPYD, TYMS, DHFR | Phase 2 | Pancreatic Adenocarcinoma; Pancreatic Cancer | Mar 2028 |
| Sun Yat-sen University | NALIRIFOX Combination chemotherapy regimen containing liposomal irinotecan (TOP1 inhibitor), oxalipl | TOP1, TOPO1 | Phase 2 | Rectal Cancers | Jun 2028 |
| Institut du Cancer de Montpellier - Val d'Aurelle | modified FOLFIRINOX regimen Combination chemotherapy: irinotecan (topoisomerase I inhibitor), oxaliplatin (platinum cr | TOPO1, TOPO2A, ERCC1 | Phase 2 | Locally Advanced Malignant Neoplasm | Sep 2029 |
| Catharina Ziekenhuis Eindhoven | FOLFOXIRI Protocol Combination chemotherapy: oxaliplatin (platinum-based alkylating agent), irinotecan (topoi | TOPO1 | Phase 2 | Rectal Cancer | Aug 2031 |
| Hospital Universitario Doctor Peset | modified TPF Modified docetaxel-cisplatin-fluorouracil chemotherapy combination | TOPO2A, TOPO1 | Phase 2 | Locally Advanced Head and Neck Squamous Cell Carcinoma | – |
| University of Colorado, Denver | NALIRIFOX Combination of liposomal irinotecan (topoisomerase I inhibitor), 5-fluorouracil (thymidyla | TOPO1, TOPO2A, TYMS | Phase 1 | Pancreatic Ductal Adenocarcinoma (PDAC) | Jul 2028 |
| The Methodist Hospital Research Institute | NALIRIFOX Topoisomerase I inhibitor (liposomal irinotecan) combined with fluoropyrimidine and platin | TOPO1 | Phase 1 | Advanced Small Intestine Cancer | Sep 2028 |
| SN BioScience | SNB-101 Nanoparticle formulation of SN-38 (topoisomerase I inhibitor) | TOPO1 | Phase 1 | Patient is Not Suitable for Complete Surgical Resection With a Cytologically or Histologically Confirmed Small Cell Lung Cancer(SCLC) | Dec 2028 |
Platinum-resistant Ovarian Cancer (2) Rectal Cancer (2) Locally Advanced Head and Neck Squamous Cell Carcinoma (1) Locally Advanced or Metastatic Small Bowel Adenocarcinoma (1) Neuroendocrine Carcinoma (1) Locally Advanced Rectal Cancer (1) Ovarian Cancer (1) Endometrial Cancer (1) Platinum-Sensitive Ovarian Cancer (1) Non-small Cell Lung Cancer (NSCLC) (1) Gastrointestinal Cancers (1) High Grade Epithelial Ovarian Cancer (1)
small molecule (15), antibody (2), mixed (1)
Sun Yat-sen University (2) Fudan University (2) Hospital Universitario Doctor Peset (1) Centre Hospitalier Universitaire Dijon (1) National Cancer Center Hospital East (1) Genmab (1) Assistance Publique - Hôpitaux de Paris (1) Rutgers, The State University of New Jersey (1) Seoul National University Bundang Hospital (1) University of Colorado, Denver (1) Peking Union Medical College Hospital (1) Seoul National University Hospital (1) SN BioScience (1) The Methodist Hospital Research Institute (1) Catharina Ziekenhuis Eindhoven (1) Dominik Paul Modest (1) Institut du Cancer de Montpellier - Val d'Aurelle (1)
TOPO2A (7) TYMS (7) DHFR (4) DPYD (2) ERCC1 (2) TOPO2 (1) XRCC1 (1) TOP1 (1) MTHFR (1) SLC22A16 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.